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Abstract 54 
The aim of this work was to obtain an intranasal delivery system with improved mechanical and 55 
mucoadhesive properties that could provide prolonged retention time for the delivery of 56 
risedronate (RS). For this, novel in situ forming gels comprising thermo-responsive star-shaped 57 
polymers, utilizing either polyethylene glycol methyl ether (PEGMA-ME 188, Mn 188) or 58 
polyethylene glycol ethyl ether (PEGMA-EE 246, Mn 246), with polyethylene glycol methyl ether 59 
(PEGMA-ME 475, Mn 475), were synthesized and characterized. RS was trapped in the selected 60 
gel-forming solutions at a concentration of 0.2% w/v. The pH, rheological properties, in vitro drug 61 
release, ex vivo permeation as well as mucoadhesion were also examined. MTT assays were 62 
conducted to verify nasal tolerability of the developed formulations. Initial in vivo studies were 63 
carried out to evaluate anti-osteoporotic activity in a glucocorticoid induced osteoporosis model 64 
in rats. The results showed successful development of thermo-sensitive formulations with 65 
favorable mechanical properties at 37°C, which formed non-irritant, mucoadhesive porous 66 
networks, facilitating nasal RS delivery. Moreover, sustained release of RS, augmented 67 
permeability and marked anti-osteoporotic efficacy as compared to intranasal (IN) and intravenous 68 
(IV) RS solutions were realized. The combined results show that the in-situ gels should have 69 
promising application as nasal drug delivery systems. 70 
 71 
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1. Introduction 81 
Star-shaped polymers are formed of a core connected to three or more linear chains (arms) with 82 
similar lengths (Daoud and Cotton, 1982). They not only have condensed structure with small 83 
volume and size compared to linear analogues but also can be decorated with different end groups 84 
that make them beneficial in different applications (Dong et al., 2015). Arms of star-shaped 85 
polymers may be either homo-, or co-polymers, hence the final properties of the resulting polymers 86 
(e.g., star-block and heterostar copolymers) may be adjusted by choosing the respective chemical 87 
structure of an arm and core, depending on the required application (Aloorkar et al., 2012). 88 
Among star-shaped polymers, polyethylene oxide (PEO) based polymers have been prepared, 89 
tested and characterized for many biomedical, pharmaceutical and tissue engineering applications 90 
(Harris, 2013). PEO based star-shaped polymers are non-ionic and biocompatible macromolecules 91 
that have high stability and solubility, hence can function to shield drug payloads from inactivation 92 
by the immune system (Lapienis, 2009). Moreover, designing polymers to have PEO chains 93 
incorporated in star architectures may be advantageous compared to linear PEO counterparts as 94 
these materials can have multiple functional groups at chain-ends or in core-components, adding 95 
to the applicability of these polymers (Gasteier et al., 2007).  96 
Recently, star-shaped PEO-based polymers have been tested for their thermoresponsive properties 97 
(Badi and Lutz, 2009). These polymers were found to have a defined lower critical solution 98 
temperature (LCST) in both water and physiological fluids. The thermoresponsive behaviour of 99 
these polymers is thought to be due to their amphiphilic nature (hydrophilic oligo(ethylene glycol) 100 
side chains and hydrophobic backbones) (Jeong et al., 2012). 101 
The copolymerization of two oligo(ethylene glycol) methacrylates with different chain lengths, 102 
namely PEGMA-ME 188 and PEGMA-ME 475 was reported and produced thermoresponsive 103 
copolymers with adjustable phase transition temperature values (Saeed et al., 2011). The reversible 104 
phase changes of these copolymers were found to be affected by their concentration and chain 105 
length as well as ionic strength (Magnusson et al., 2008). Hence, these polymers were suggested 106 
as promising candidates for the formulation of thermoresponsive materials. Oligo(ethylene 107 
glycol)-based thermoresponsive materials have now been developed in the form of dendrimers, 108 
microgels, and added to silica particles, gold particles, block copolymer aggregates, carbon 109 
nanotubes, and planar surfaces (Lutz, 2011). 110 
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Hydrogels were used for different applications in drug and cell delivery as well as in tissue 111 
engineering as polymer scaffold (Cespi et al., 2014; Caló and Khutoryanskiy, 2015). In situ gelling 112 
hydrogels have been exploited for drug delivery through various administration routes and 113 
presented a great interest for nasal delivery (Cai et al., 2011; Galgatte et al., 2014; Wavikar et al., 114 
2017). 115 
Osteoporosis and Paget’s disease of bone are major problems in women and geriatric patients 116 
(Riggs and Melton, 1995). In this regard, various pharmacological molecules have been attempted 117 
to accelerate new bone formation such as recombinant human fibroblast growth factor-2, 118 
thrombin-related peptide, bone morphogenetic protein-2 and bisphosphonates (Hirabayashi and 119 
Fujisaki, 2003). Bisphosphonates, as pyrophosphate analogues, possesses a known affinity for 120 
bone tissue and an outstanding antiresorptive and osteoclast inhibitory potential (Czuryszkiewicz 121 
et al., 2005). These types of drugs are effective in the treatment of Paget’s disease, osteoporosis, 122 
multiple myeloma, bone metastases, fibrous dysplasia of bone, and breast cancer (Czuryszkiewicz 123 
et al., 2005; Nancollas et al., 2006). Nitrogen containing bisphosphonates (e.g.  Risedronate (RS)) 124 
are many times more potent than the non-nitrogen ones. Despite the interest in fabricating RS 125 
carrier platforms, its high polarity and hydrophilicity lead to very poor oral bioavailability (< 1%). 126 
In addition, RS exacerbates serious side effects in the gastrointestinal tract (GIT) such as 127 
oesophagitis, ulcers and gastritis. Various administration routes for RS, including intravenous, 128 
subcutaneous and intramuscular routes, have been attempted in order to improve its poor oral 129 
bioavailability (< 1%) and therapeutic efficacy as well as minimizing its side effects (Salzano et 130 
al., 2011). Following intravenous (IV) administration, calcium complexes in the blood are formed 131 
resulting in possible occurrence of renal failure (Toussaint et al., 2009). Furthermore, injection of 132 
sodium salts was reported to develop pain and tissue necrosis at the injection site. Accordingly, a 133 
focus of current research is localized delivery of RS via nasal and pulmonary routes (Fazil et al., 134 
2016; Nasr et al., 2011). 135 
In the present work, polymers of star-shaped PEGMA-ME 188 or PEGMA-EE 246 with and 136 
without PEGMA-ME 475 were synthesized and characterized for preparing thermoresponsive 137 
hydrogels. We aimed to investigate the utilization of the prepared platforms with PEGMA-ME 138 
188 or the PEGMA-EE 246 -co- PEGMA-ME 475 as bio-applicable thermogels with optimal 139 
thermoresponsive and mucoadhesive properties in physiological conditions for the nasal delivery 140 
of RS. To our knowledge, this is the first study to demonstrate star-shaped poly(oligoethylene 141 
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glycol) copolymers in situ gels as nasal delivery carriers for RS and to evaluate their in vivo 142 
efficacy for the treatment of osteoporosis in rat models. 143 
 144 
 145 
2. Experimental 146 
2.1. Materials 147 
All solvents and reagents were of analytical or HPLC grade and purchased from Sigma Aldrich 148 
(UK) or Fisher Scientific (UK) unless otherwise stated. Deuterated solvents were from Sigma 149 
Aldrich (UK) or Cambridge Isotopes (UK). Monomers used in this study (Polyethylene glycol 150 
methyl ether (PEGMA-ME 188, Mn 188), polyethylene glycol ethyl ether (PEGMA-EE 246, Mn 151 
246), and polyethylene glycol methyl ether (PEGMA-ME475, Mn 475) were purchased from 152 
Sigma Aldrich (UK) and purified before use by passing through a column filled with neutral 153 
alumina. 2,2- azobisisobutyronitrile (AIBN) was purchased from Sigma Aldrich (UK) then 154 
recrystallized from methanol. Pentaerythritol Tetra (3-mercaptopropionate) (PETMP) and 2-155 
butanone were used as received from Sigma Aldrich (UK). Risedronate sodium was kindly 156 
supplied by SPIC Pharma (India). Spectra/Por dialysis membrane, 12,000–14,000 molecular 157 
weight cutoff, was purchased from Spectrum Laboratories (Canada). MTT (3-(4,5-158 
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide), HEPES buffer, gentamycin, 159 
dimethylsulfoxide and sodium lauryl sulphate (SLS) from Sigma-Aldrich (UK). Foetal calf serum, 160 
Minimum Essential Medium (MEM), from Lonza (Belgium); and L-glutamine GIBCO®, were 161 
purchased from Thermo Fisher Scientific (USA).  162 
 163 
2.2 Polymer synthesis and telomerization kinetics 164 
Polymers were prepared by free radical polymerization (Fig. S1). Monomers were weighed into a 165 
round bottom flask then PETMP and 20 ml of 2-butanone were added. Lastly AIBN was added 166 
and the mixture was degassed with nitrogen for 25 minutes. Then the solution temperature was 167 
elevated to 70 °C and polymerization was allowed to proceed at that temperature for 2 h. The 168 
reaction was then stopped by cooling the reaction vessel in liquid nitrogen. The polymer was 169 
purified from excess monomers and reagents by precipitation three times in hexane. 170 
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Telomerization kinetics of Poly(PEGMA188-ME) and Poly(PEGMA246-EE) were examined by 171 
following the concentrations of monomers and telogen (PETMP) throughout the reaction. Samples 172 
were collected at 0, 30, 45, 60, 90, 120, 150 and 180 min and the reaction was stopped by cooling 173 
them in ice. 174 
Samples were evaluated by 1H-NMR in CDCl3 to detect monomer PEGMA188 for 175 
Poly(PEGMA188-ME) and PEGMA246-EE for Poly(PEGMA246-EE) conversion by comparing 176 
the integration of monomer vinylic protons to polymer methine protons. The remaining sample 177 
was precipitated in hexane then filtered and the filtrate was evaporated under vacuum. The residue 178 
left after evaporation was dissolved in water then any PETMP left was determined by iodine 179 
titration to determine telogen conversion (Loubat and Boutevin, 2001). 180 
 181 
2.3 Characterization of the synthesized polymers 182 
2.3.1 FTIR characterization  183 
FTIR spectra of the polymers were recorded in the range of 4000-400 cm-1 on a Nicolet 6700 FTIR 184 
(Thermo Scientific, USA), equipped with an attenuated total reflectance (ATR) accessory 185 
providing an analysis of the sample surface. Polymeric samples were loaded on KBr discs without 186 
previous treatments or special preparation techniques. All spectra were recorded at ambient 187 
temperature under vacuum to remove air humidity contribution at a resolution of 4 cm-1 and 16 188 
scans were recorded for each measurement to obtain an adequate signal to-noise ratio. 189 
 190 
2.3.2 Nuclear Magnetic Resonance Analysis (1H-NMR) 191 
1H-NMR spectra were recorded on a Bruker 400 spectrometer (Bruker Avance III, Switzerland) at 192 
399.8 MHz (1H) in chloroform-d solutions. All chemical shifts are reported in ppm relative to 193 
TMS. 194 
 195 
2.3.3. Gel Permeation Chromatography (GPC) 196 
As shown in Table 1, the number average molecular weight (Mn), weight average molecular weight 197 
(Mw) and polydispersity index (Mw/Mn) of the synthesised polymers were determined using gel 198 
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permeation chromatography device (PL-50 PolymerLabs, UK) equipped with refractive index 199 
detector. The device columns (30 cm PLgel Mixed- C, 2 in series) were eluted with chloroform 200 
and calibrated with polystyrene standards (Mw=162–371100Da) (PolymerLabs, UK).  201 
Standard calibrations as well as analysed samples were maintained at 40°C during analysis and a 202 
flow rate of eluent was set at 1ml/min for all experiments. All samples were dissolved in HPLC 203 
grade chloroform and filtered using 0.2 μm filter before injecting 100 μL aliquots.  204 
 205 
2.3.4. Rheometrical characterizations 206 
The rheological measurements were performed using Physica Rheometer (Anton Paar, USA), 207 
equipped with parallel plate geometry (25 mm diameter) and the gap distance between two plates 208 
was set as 0.5mm. RheoPlus Software (Version 3.6x) was used for measuring data.  209 
Temperature Ramp experiments were recorded at 0.05% strain at a frequency = 1 rad s-1 with a 210 
heating rate of 1˚C/ min from 10 to 40˚C. Before running the experiment, the lower plate and the 211 
PP25 were left in contact for 5 min at 10˚C. Afterwards, 300 μl of sample was applied on the lower 212 
plate. The sample was equilibrated at the desired temperature (10˚C) for 4 min before starting the 213 
run. The tests have been performed using a fresh aliquot of sample.  214 
 215 
2.3.5. UV/ Visible spectroscopy (Temperature dependent turbidity) measurement 216 
A DU 800 UV spectrophotometer (Beckman Coulter, USA) with a thermostat was used for 217 
measuring the change in absorption of polymeric sample solutions over a temperature range of 10–218 
50 °C at a wavelength of 550.0 nm. The temperature was controlled and measured using a Peltier 219 
plate heating system (Beckman Coulter, USA) and was increased at a rate of 1 °C/min.  220 
 221 
2.4. Scanning Electron Microscopy (SEM) 222 
Gel surface morphologies were imaged via SEM. Samples were prepared by spreading freeze dried 223 
gels (Poly(PEGMA188-ME-co-PEGMA475-ME) and Poly(PEGMA246-EE-co-PEGMA475-224 
ME)) on an aluminium stub coated with carbon tape. Samples were then coated with a thin layer 225 
of gold (Blazer SCD 030 Sputter coater, Blazer Union Ltd, Liechtenstein) for 3 minutes, then 226 
images were recorded using a JEOL 6060V scanning electron microscope (JEOL Ltd, UK) at an 227 
accelerating voltage of 30kV. 228 
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 229 
2.5. Incorporation of RS in thermoresponsive gels and pH determination 230 
All the co-polymers used in this study were prepared in cold ultrapure water (15-30% w/w), gels 231 
for nasal delivery were prepared to contain 5% mannitol as a tonicity adjuster. The solutions were 232 
kept in a refrigerator for at least 24 h to ensure complete dissolution and formation of clear 233 
homogeneous solutions. The model hydrophilic drug, RS, at a concentration of 0.2% w/v was then 234 
incorporated in the prepared solutions by simple mixing.  235 
The developed formulations were evaluated for pH by using a pH meter (Model 3510, Jenway, 236 
UK). 237 
  238 
 239 
2.6. Viscosity determination of RS loaded thermoresponsive gels 240 
The sol–gel transition behavior of the hydrogels was further evaluated by viscosity measurements. 241 
The viscosity of the instilled formulation into the nose is considered to be very important for 242 
determination of nasal residence times of drugs. The prepared formulations were allowed to gel at 243 
physiological temperature and then the viscosity was determined by a DV-E Viscometer 244 
(Brookfield Engineering Laboratories, USA) using spindle no 52 at speeds ranging from 0.5 to 245 
100 rpm (shear rates 1 to 200 sec-1) and over 10% torque. By plotting rheograms of viscosity values 246 
versus shear rate, the flow pattern was checked. 247 
 248 
2.7 Bioadhesion Strength of RS loaded thermoresponsive gels 249 
To quantify mucin-polymer mucoadhesive strength of gel formulation, a simple viscometric 250 
method was used as previously described by (Hassan and Gallo, 1990). The viscosities of 15% 251 
(w/v) porcine gastric mucin dispersions in normal saline, co-polymer solutions and mucin–252 
hydrogels (RS loaded Poly(PEGMA188-ME-co-PEGMA475-ME) gel (F2) and RS loaded 253 
Poly(PEGMA246-EE-co-PEGMA475-ME) gel (F4)) mixtures were measured at 37 °C using 254 
Brookfield viscometer. 255 
The viscosity coefficient was then determined by equation 1: 256 
ƞt = ƞm + ƞp + ƞb                        (1) 257 
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Where ƞt is the viscosity coefficient of the system, ƞm and ƞp are the individual viscosity 258 
coefficients of mucin and polymers, respectively, and ƞb is the viscosity component due to the 259 
mucoadhesion. 260 
 261 
2.8 In vitro drug release study 262 
The freshly prepared RS loaded hydrogels were used in in vitro release study similar to the one 263 
attempted by (Nasr et al., 2013). In details, hydrogels equivalent to 2 mg RS were loaded in 264 
cylinders of cellulose acetate membrane and placed in 15 mL vials containing 7.5 ml physiological 265 
normal saline (Wu et al., 2007) maintained at 37 °C in shaker water bath (Kottermann GmbH, 266 
Uetze/Hanigsen, Germany) at 50 rpm. As a control, the release of 2 mg RS solution was also 267 
performed. At selected time intervals (1, 2, 4, 6, 8, 24, and 48 h), 0.5 mL was sampled from vials 268 
and replaced with an equal volume of fresh pre-warmed saline.  269 
The quantity of RS released was determined using UV spectrophotometry (UV-Vis 270 
spectrophotometer, UV-1601PC, Shimadzu, Japan) at 262 nm. The results of the release 271 
experiments are shown as cumulative drug percentage released plotted as a function of time.  272 
The release profiles was compared using similarity factor (f2) according to (Moore, 1996) 273 
independent mathematical approach The similarity factor (f2) was calculated according to equation 274 
2: 275 
𝑓2 = 50𝑙𝑜𝑔 {[1 + (
1
𝑛
)∑ (𝑅𝑡 − 𝑇𝑡)2𝑛𝑡=1 ]
−0.5
× 100}                (2) 276 
 277 
where n is the number of time points, Rt and Tt are the percent drug released from F2 and F4 at 278 
time t. f2 value between 50 and 100 indicate that the release profiles are similar. 279 
 280 
2.9 Ex vivo permeation 281 
An ex-vivo nasal permeation study was performed in order to evaluate nasal absorption of RS from 282 
the prepared hydrogels. The study was performed by introducing 100 µL of the prepared 283 
formulations in the donor compartment of a Franz-type static glass diffusion cell (Variomag 284 
Telesystem, H + P Labortechnik, Germany) with a 7.5 mL receptor volume and diffusion surface 285 
area: 1.77 cm2. The hydrogels were placed on a freshly separated sheep nasal mucosa, positioned 286 
between the donor and receptor compartments. The receptor compartment was filled with 287 
physiological saline (0.9 %, w/w), maintained at 37 ± 0.5 °C. Samples (0.5 ml) were withdrawn 288 
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from the receptor fluid at appropriate time intervals up to 48 h, and replaced with 0.5 ml of fresh 289 
saline. The results of permeation studies are represented as cumulative drug amount (µg) 290 
permeated per unit of surface area (cm2) versus time. The steady state flux (J, μg/cm2/h) was 291 
determined from the slope of the linear profiles. 292 
 293 
2.10 In vivo study 294 
In the current study, we tried to evaluate role of RS in osteoporosis model induced by 295 
dexamethasone sodium phosphate. All study procedures were evaluated and approved by the 296 
Research Ethics Committee of the Faculty of Pharmacy, Ain Shams University. A total of 24 297 
female Albino rats weighing 225 to 250 g were selected for this study. Animals were housed under 298 
controlled environmental conditions and were maintained in plastic cages with free access to food 299 
and water and were kept at a constant temperature of 20-24°C with 12 h light/dark cycle.  300 
 301 
2.10.1 Glucocorticoid induced osteoporosis model in rats  302 
Following 7 days of acclimatization, glucocorticoid-induced osteoporosis (GIO) was induced in 303 
female Albino rats by subcutaneous (SC) administration of Fortecortin® (dexamethasone sodium 304 
phosphate) at 8 mg/kg body weight per 7 days for 4 weeks (Fazil et al., 2016). Weights of rats 305 
were observed during induction of osteoporosis and their treatment.  306 
 307 
2.10.2 Animal groups 308 
The rats were divided into six groups (each group contained 4 rats) as follows: 309 
Group I (S): Received 30 µl intranasal (IN) normal saline (S) through micropipette attached to a 310 
polyethylene tube (negative control group). Group II (DEX): was given subcutaneous (SC) 311 
dexamethasone sodium phosphate (DEX) by above mentioned dose (toxic control group). Group 312 
III (DEX+ IN RS): was given DEX plus receiving IN RS solution (1mg/kg) (Fujita et al., 2011). 313 
Group IV (DEX+ IV RS): was given DEX plus receiving IV RS solution (1mg/kg). Group V 314 
(DEX+ IN F2): was given DEX plus receiving IN F2 in situ thermoresponsive gel (volume 315 
equivalent to RS 1mg/kg). Group VI (DEX+ IN F4): was given DEX plus receiving IN F4 in situ 316 
thermoresponsive gel (volume equivalent to RS 1mg/kg). 317 
 318 
2.10.3 Biochemical analysis of bone turnover markers 319 
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At the end of the study (28 days), animals were killed under general anaesthesia with diethyl ether 320 
after blood collection from retro orbital plexus. Blood was centrifuged at 5000 rpm for 10 min and 321 
serum stored immediately at -20°C for analysis. Serum alkaline phosphatase, serum calcium level, 322 
serum inorganic phosphorus level and serum creatinine were estimated. The values of blood 323 
biochemistry were measured in Ain Shams Laboratory Center, Cairo, Egypt using Roche 324 
biochemical regeants via photometric assay (Hitachi 917 autoanalyzer, Roche Diagnostics, USA)  325 
 326 
2.10.4 Histological study of bone internal structure 327 
Autopsy samples were taken from the femur bone of rats in different groups and fixed in 10% 328 
formal saline for twenty-four hours then decalcification in formic acid. Washing was done with 329 
water then alcohol was used for dehydration. Specimens were cleared in xylene and embedded in 330 
paraffin wax melted at 56°C in an oven for twenty-four hours. Paraffin tissue blocks were prepared 331 
for sectioning at 4 microns thickness by a sledge microtome (Rotary Leica RM2245,USA). The 332 
obtained tissue sections were collected on glass slides, deparaffinised, stained by hematoxylin & 333 
eosin stain for examination via microscopy (Axiostar Plus, Zeiss, USA) (Banchroft 1996). 334 
 335 
2.11 Evaluation of nasal cytocompatability  336 
MTT assays were used to evaluate the in vitro cytotoxicity of the prepared gels on Calu-3 cells. 337 
Brieﬂy, cells were seeded at a density of 1× 104 cells/well in 96-well plates and incubated at 37 °C 338 
in a humidified atmosphere (95% RH) with 5% v/v CO2 (Humid CO2 incubator, Shel lab 2406, 339 
USA). Seven aliquots of the co-polymers solutions (7.81-15.62-31.25-62.5-125-250-500 μg/mL) 340 
were added to the wells, followed by incubation for another 24 h.  Both sodium dodecyl sulphate 341 
treated and untreated cells were used as positive and negative controls respectively. After 24 h of 342 
incubation, 20μL of MTT solution (5 mg/mL in phosphate buﬀered saline pH 7.4 was added to 343 
each well and incubated at 37°C for 4 h. then, MTT solution was removed and DMSO was added 344 
to solubilize the formed formazan. The absorbance was read at 570 nm on a microplate reader 345 
(Tecan Sunrise®, Switzerland). Cell metabolic activity as a proxy for viability (%) was calculated 346 
according equation 3:  347 
 348 
Cell metabolic activity (viability, %) = (Absorbance test/Absorbance control) X 100         (3) 349 
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Where the absorbance control was the absorbance of untreated cells in the control wells.  350 
 351 
2.12 Statistical analysis 352 
The measured data were shown as mean of 3 or 4 determinations ± standard deviation (SD).  The 353 
mean values were analysed for their statistical significance using either Student′s t test or ANOVA 354 
using Graph Pad Instat software program version 3.06 (GraphPad Software, Inc., USA). p-value ≤ 355 
0.05 was chosen as the criterion for statistical significance.  356 
 357 
3. Results and discussions 358 
3.1. Preparation of gel components and telomerization kinetics 359 
Thermoresponsive polymers were synthesised by free radical polymerization using PETMP as a 360 
chain transfer agent. PETMP was chosen as the transfer agent in order to produce star-shaped 361 
polymers. The homopolymers of PEGMA-ME 188 and PEGMA-EE246 were prepared as controls 362 
to establish telomerisation kinetics before being copolymerized with the more hydrophilic 363 
monomer PEGMA-ME475 to adjust the gelation temperature to a value > 30°C (Fig. S2 and Table 364 
1). 365 
The PEGMA based polymers were prepared aiming to combine the advantageous properties of 366 
polyethylene glycol (non-toxic, non-immunogenic) and thermosensitivity in one macromolecule. 367 
Table 1 demonstrates the molar masses and characteristics of the homo- and co-polymers.  368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
Table 1. Summary of the polymers synthesized in this study 378 
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Polymer structure 
Mn 
(kDa) 
PDI 
Tc 
(°C) 
PEGMA475 
(%) 
CT 
Poly(PEGMA188-ME) 38.9 1.9 26 0 0.97 
Poly(PEGMA188-ME-co-PEGMA475- ME) 36.2 2.1 32 16 --- 
Poly(PEGMA246-EE) 35 2.3 25 0 0.93 
Poly(PEGMA246-EE-co-PEGMA475-ME) 43 2.2 31 10 --- 
 379 
The control of polymer architecture through the use of polyfunctional chain transfer agent 380 
in free radical polymerization was investigated, both theoretically and experimentally. 381 
Yuan et al studied the telomerization of methyl methacrylate with the tetrafunctional 382 
transfer agent PETTMP and found a CT to be 0.64 (Yuan and Di Silvestro, 1995). It is 383 
assumed that the smaller the value of transfer constant (CT ≈1) is an indication of 384 
telomerization reaction efficiency (Loubat and Boutevin, 2001; Pardal et al., 2009). 385 
There are several methods of determining the transfer constant (CT) of the transfer agent. The most 386 
widely used one is given by (O'Brien and Gornick, 1955). This method requires a plot of ln[T0]/[T] 387 
versus ln [M0]/[M] where[T0], [T], [M0] and [M] are the molar concentrations of telogen and 388 
monomer at time 0 and time t respectively where the value of CT can be determined from the slope 389 
of the line obtained. 390 
This method was applied to the telomerization of PEGMA188-ME and PEGMA246-EE in the 391 
presence of PETTMP as a telogen under nitrogen, in 2-butanone at 70 °C, in the presence of AIBN 392 
as initiator. Each reaction was monitored by sampling, and each aliquot was quenched in ice to 393 
stop the reaction. The monomer (M) and telogen (T) conversions were determined, respectively, 394 
with 1H NMR and iodine titration as explained in the experimental section. 395 
From the change of each monomer and telogen concentration in the course of their telomerization, 396 
the CT values were determined for Poly(PEGMA188-ME) and Poly(PEGMA246-EE) and found 397 
to be 0.97 and 0.93 respectively, indicating efficient telomerization reaction (Fig. S2).  398 
 399 
3.3 Polymer characterization  400 
The chemical structure of copolymers was characterized by FTIR, 1H-NMR, and GPC. 401 
 402 
3.3.1 FTIR 403 
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In order to confirm the formation of the polymers, FTIR spectra were performed as shown in Fig. 404 
S3. In the generated spectra, the bands of 1726 and 1113 cm-1 were respectively assigned to the 405 
C=O and C-O stretching vibrations for carbonyl group of carboxylic ester, the wide band around 406 
3423 cm-1 to the O-H stretching vibration, the bands of 2871 cm-1 and 1470 to 1380 cm-1 to the 407 
stretching and bending vibrations of methylene (-CH2). The absence of the acrylate group at the 408 
range of 1620 - 1650 cm-1 indicates that acrylate groups were depleted and hence, the successful 409 
formation of polymers by free radical polymerisation (Lee et al., 2003). 410 
 411 
3.3.2 NMR 412 
The polymers were characterised by NMR spectroscopy as shown in Fig. S4. 413 
1H NMR spectra were recorded in CDCl3 using Bruker 400 MHz. The molar fraction of 414 
PEGMA475-ME in Poly(PEGMA246-EE-co-PEGMA475-ME) was calculated from 1H NMR 415 
spectra by comparing the overall integration of the methoxy protons (3.41 ppm) to the 416 
integration at 1.23 ppm for the 3 terminal protons of ethoxy moiety of PEGMA246-EE. 417 
 418 
Poly(PEGMA188-ME) and Poly(PEGMA188-ME-co-PEGMA475-ME) 419 
1H NMR (400 MHz, CDCl3, δ, ppm): 4.25 (-CO-OCH2CH2), 4.1-4.2 (CCH2OCOCH2-), 3.5-3.75 420 
(-CH2OCH2CH2O-), 3.35-3.41 (CH3O-), 2.3-2.5 (OCOCH2CH2S-), 1.7-2.01 (-SCH2C(CH3)-), 421 
0.72-1.16 (-CH2C(CH3)-). 422 
 423 
Poly(PEGMA246-EE) 424 
1H NMR (400 MHz, CDCl3, δ, ppm): 4.22 (-CO-OCH2CH2), 4.1 (CCH2OCOCH2-), 3.5-3.7 (-425 
CH2OCH2CH2O-), 3.4 (CH3CH2O-), 2.2 (OCOCH2CH2S-), 1.62-2.06 (-SCH2C (CH3)-), 1.23 426 
(CH3CH2O-),0.72-1.16 (-CH2C (CH3)-). 427 
  428 
Poly(PEGMA246-EE-co-PEGMA475-ME) 429 
1H NMR (400 MHz, CDCl3, δ, ppm): 4.3 (-CO-OCH2CH2), 4.1 (CCH2OCOCH2-), 3.5-3.7 (-430 
CH2OCH2CH2O-), 3.47 (CH3CH2O-), 3.41 (CH3O-), 2.3-2.45 (OCOCH2CH2S-), 1.62-2.06 (-431 
SCH2C (CH3)-), 1.23 (CH3CH2O-), 0.72-1.16 (-CH2C(CH3)-). 432 
 433 
3.3.3 Gel permeation chromatography (GPC) 434 
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Fig. S5 and Table 1 present the molar masses relative to polystyrene standards for the respective 435 
polymers. The polymers synthesised had a large polydispersity index, as expected for polymers 436 
prepared by free radical polymerization methods. Conventional free radical methods were used 437 
since they do not require complex conditions or metals, employed in controlled polymerisations 438 
that might be difficult to eliminate and which could otherwise present a source of toxicity (Johnson 439 
et al., 2008) when used with cells (Chen et al., 2006). Prior reports have shown that high 440 
polydispersity polymers can still form thermogelling solutions (Lietor-Santos et al., 2009). 441 
 442 
 443 
3.6. Rheological property  444 
Gels made from the prepared polymers were characterised by experiments to measure their 445 
elastic/storage (G`) and the viscous (G``) moduli. The variation of G` with temperature was 446 
apparent in temperature/gel moduli plots of a representative gel (Fig. S6A). This could confirm 447 
the high dependency of intermolecular attraction between polymer chains, and hence the gel 448 
elasticity, on temperature. Below the Lower Critical Solution Temperature (LCST) of the polymers 449 
(as estimated from the cloud point), they behaved as viscous fluids with G``> G`. At temperature 450 
values around the LCST, a crossover occurred, with G`>G``, indicative of gel formation. Both 451 
moduli increased with temperature, with G` remaining higher than G``.  452 
The ability to manipulate the properties of the gel by changing the thermoresponsive polymer is 453 
shown in Fig. S6B. For equivalent composition ratios, gels formed above LCST using 454 
homopolymers were of higher moduli than copolymers containing PEGMA475. The rheology 455 
experiments thus indicated that the mechanical properties of the gels were able to be tuned by 456 
composition, suggesting a simple way of tailoring the gel properties for a particular application.  457 
 458 
3.3.4. Cloud point determination 459 
Thermoresponsive polymers undergo a coil-to-globule transition at the lower critical solution 460 
temperature (LCST) and become water insoluble (Liu et al., 2009). When the polymers are in the 461 
collapsed state their solution becomes turbid as a result of polymer chain aggregation. 462 
The solution turbidity starts at the cloud point temperature (Cpt) and this can be easily determined 463 
experimentally by light transmission measurement. Cloud point temperatures were measured to 464 
estimate the LCST for each polymer (Alava and Saunders, 2006) as shown in table 1.  465 
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Phase transitions temperatures of the polymers were modulated by copolymerization of 466 
hydrophobic OEGMA component with the hydrophilic PEGMA monomer (Table 1, Fig. 1). We 467 
were interested in polymers that would exhibit phase transitions at, or close to, body temperature. 468 
it was found that the statistical FRP copolymer of OEGGMA-co-PEGMA (95/5 monomer-feed 469 
ratio) met this criterion. As expected, the cloud point temperatures were higher for PEGMA-470 
ME475 copolymers than homopolymers, owing to the presence of hydrophilic monomer. 471 
PEGMA-ME475 had the effect of facilitating polymer chain dehydration to happen at higher cloud 472 
point value. Similar cloud point values have been reported previously for a number of linear 473 
thermosensitive polymers (Magnusson et al., 2008). Hence, Poly(PEGMA188-ME-co-474 
PEGMA475-ME) and Poly(PEGMA246-EE-co-PEGMA475-ME) were suitable for drug loading 475 
and its nasal delivery. 476 
 477 
 478 
Fig. 1. Cloud point measurements of polymers using UV–visible turbidimetry experiments at 550 nm in 479 
water (1 mg/mL) versus temperature.  480 
 481 
3.4 SEM imaging 482 
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Fig. 2 depicts typical SEM micrographs of freeze-dried Poly(PEGMA188-ME-co-PEGMA475- 483 
ME) and Poly(PEGMA246-EE-coPEGMA475-ME) hydrogels the microstructure of the interior 484 
of the freeze-dried hydrogels was revealed. Poly(PEGMA188-ME-coPEGMA475-ME) hydrogels 485 
had relatively regular pores of tens to hundreds of micrometres in size formed through well-486 
connected gel matrices.  487 
The morphology of Poly(PEGMA246-EE-co-PEGMA475-ME) appeared somewhat different, 488 
where an irregular, entangled fibrous morphology is noticed. It is obvious that gel matrices 489 
appeared porous with channels/voids of 5–20 µm. Calculations indicated that this void volume 490 
was equivalent to 60–75% porosity in the gels studied.  491 
The porous network structure of these hydrogels with their biodegradability and relatively strong 492 
gel strength suggested that these materials might be useful as drug delivery biomaterials the high 493 
internal surface areas with low diffusional resistance would be favorable for small drug molecules 494 
like RS to move freely in the polymeric network.  495 
 496 
Fig. 2. Representative Scanning Electron Micrograph of (a) F2 and (b) F4. 497 
 498 
3.5. Incorporation of RS in thermoresponsive gels and pH determination 499 
Based on a preliminary study, the co-polymer solutions (Poly(PEGMA188-ME-coPEGMA475-500 
ME) and Poly(PEGMA246-EE-coPEGMA475-ME)) at 30% were chosen, owing to their 501 
capability to form hydrogels upon heating in a water bath at 37°C. The developed in situ gels were 502 
loaded with RS (0.2% w/v) by simple mixing (F2 and F4 respectively). The image of pre-gelled 503 
solution and formed hydrogel are shown in Fig. 3.  504 
The pH of nasal formulations should be such that the formulation will be stable at that pH and at 505 
the same time there would be no irritation to the patient upon administration. Tolerable non-506 
A B 
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irritable nasal formulations should have pH range in between 4.5 to 6.5. The pH values of 507 
hydrogels were found to be within the physiologic range of nasal application amounting of 5.55 ± 508 
0.02 and 5.79 ± 0.04 for F2 and F4, respectively.  509 
 510 
 511 
 512 
Fig. 3. Sol-gel phase transitions of F2 in (a) a sol state at 25 °C, (b) gel state at 37 °C. 513 
 514 
 515 
3.6 Viscosity determination of RS loaded thermoresponsive gels 516 
Concerning rheological measurements, the rheograms obtained for the two investigated gels at 517 
37°C displayed the pseudoplastic and shear-thinning behaviour (Fig. 4). Such rheological patterns 518 
could therefore be preferred so that the viscosity decreases, facilitating the flow of the in-situ gel 519 
upon application for intranasal use. 520 
 521 
A    B 
 20 
 522 
Fig. 4. Viscosity measurements of the investigated gel formulations. Data are reported as the mean of three 523 
independent experiments. 524 
  525 
3.7 Bioadhesion strength of RS loaded thermoresponsive gels 526 
When considering nasal delivery, it is highly desirable to formulate bioadhesive delivery vehicles 527 
to enhance their localization and retention time in the nasal area, thus intensifying the contact with 528 
nasal mucosa for the drug absorption. This was the basis for investigating the mucoadhesive 529 
properties for the prepared formulae in this study. The viscosity of the prepared formulae plays an 530 
important role in determining the mucoadhesive properties (Suvannasara et al., 2013). Therefore, 531 
in this work, mucoadhesive force between the interacting polymers (F2 and F4) and the mucin 532 
were elucidated based on viscosity data.  533 
The results indicated rheological synergism and promising mucin-thermoresponsive gels 534 
association. The viscosity values of mucin-gels mixtures showed values of 1.85 ± 0.07 and 1.64 ± 535 
0.016 Pa·s for F2 and F4 respectively. Such values were revealed to be higher than the sum of the 536 
corresponding viscosity values of the separate components of mucin (1.14 ± 0.11 Pa·s) and 537 
individual co-polymers (respective 0.10 ±0.04 and 0.096 ± 0.008 Pa·s values for 538 
Poly(PEGMA188-ME-co-PEGMA475-ME) and Poly(PEGMA246-EE-co-PEGMA475-ME). 539 
Furthermore, F2 exhibited a significantly higher component of mucoadhesion (0.6 Pa·s), almost 540 
1.51fold higher than that for F4 (0.39 Pa·s) (P˂0.001). Therefore, such formulations were 541 
considered potential mucoadhesive intranasal drug delivery systems.  542 
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It was found that incorporating high molecular weight PEG based polymers onto the surfaces of 543 
hydrogels and hydrogel microparticles enhanced mucoadhesion. PEG chains are able to 544 
interpenetrate and associate with mucin by forming hydrogen bonds with its carbohydrate regions 545 
hence acting as a ‘glue’ (Wang et al., 2008) (Maisel et al., 2016). 546 
 547 
3.8 In vitro drug release 548 
RS was utilized as a hydrophilic model drug to evaluate the feasibility of F2 and F4 for its sustained 549 
delivery. RS has a log octanol/water partition-coefficient of -3.48 (Biernacka et al., 2013). Free 550 
RS reached 100% release within 4 hours owing to its high polarity and hydrophilicity, similar to 551 
that previously reported (Nasr et al., 2011). The release profile of RS from hydrogels is 552 
investigated as shown in Fig. 5. The data indicates that 63 and 61.5 % of RS was released in 2 days 553 
for F2 and F4 respectively under sink conditions. Such similar percent RS release was confirmed 554 
by similarity factor calculated value (f2 = 72.37). 555 
RS exhibited an initial burst release from both hydrogel matrices reaching values of 43.7 and 37 556 
% at first hour respectively followed by slowed and sustained release rate till the end of 557 
experiment. The burst release of RS release was more likely due to the presences of RS on the 558 
surface or distributed in the hydrogels network during the gelation process. Besides, the 559 
hydrophilic RS might possess a higher tendency to partition in the hydrophilic domain of the 560 
hydrogel and to diffuse rapidly and easily through the hydrogel into the release medium. The 561 
porous network of the prepared matrices, observed in SEM images, confirmed the previous 562 
hypothesis, indicating the diffusion-controlled drug release.  563 
After that, the entrapped RS into the hydrogel was released slowly due to the swelling and 564 
degradation of the hydrogel. Because the hydrogel did not degrade completely during the time of 565 
investigation, some part of the RS entrapped in the inner core of the hydrogel would not be released 566 
until the hydrogel was degraded entirely.  567 
It is worthy to note that the prepared hydrogels (F2 and F4) exhibited a wide range of erosion rates 568 
and maintained their mass for over two days. The percentage of gels that remained after 2 days 569 
was 25 and 30% for F2 and F4, respectively (data not shown). F4 showed significantly higher 570 
resistance against mass erosion in aqueous solution as compared to F2. This might be attributed to 571 
its content of the longer chain length of PEGMA246-EE. Higher viscosity of the in situ platform 572 
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might also slow the degradation. Consequently, such in situ gels seemed to be more functional for 573 
a sustained RS delivery. 574 
A similar release profile was observed for an intranasal thermosensitive hydrogel utilizing 575 
quaternized chitosan and poly(ethylene glycol) (Wu et al., 2007). Such a biphasic release pattern 576 
was a common finding seen in previous research papers studying the release of different 577 
biopharmaceuticals from thermosensitive hydrogels (Rangabhatla et al., 2016; Wu et al., 2007). 578 
 579 
 580 
Fig. 5. In vitro release profiles of RS and RS loaded gel formulations over 48 h.  Data are reported as the 581 
mean ± S.D. of three independent experiments.  582 
 583 
3.9. Ex-vivo permeation 584 
Fig. 6 illustrates the amount of RS permeated per unit surface area of the sheep nasal mucosa 585 
versus time for F2 and F4, using RS solution as a comparison. RS-loaded formulae exhibited 586 
higher permeation as compared to RS solution. According to the biopharmaceutics classification 587 
system, RS belongs to class III (high solubility/low permeability) (Fazil et al., 2016; Jung and Han, 588 
2014).  589 
Permeation enhancement potential of the two investigated formulations could be due to the 590 
surfactant properties of PEG ethers in the polymers (Casiraghi et al., 2015), possibly solving the 591 
permeability problem and low flux of RS (Nam et al., 2011). Additionally, the hydrogels took 592 
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more time for degradation in the biological system which showed permeation over 48 h. Moreover, 593 
the mucoadhesive capability of the thermogels might contribute to nasal retention which plays a 594 
very important role in transnasal penetration promoting effects.  595 
The flux for F2 and F4 was found to be 70.9 and 94 µg/cm2h-1, respectively, while only flux value 596 
of 43.52 µg/cm2h-1 was depicted for RS solution, proving that the RS containing formulae 597 
possessed high penetration through the nasal mucosa. Similar to what was obtained in the in vitro 598 
release experiment, there was no statistically significant difference between the cumulative amount 599 
of RS from F2 and F4 permeated after 48 h (p ˃0.05) (Maisel et al., 2016).  600 
 601 
 602 
Fig. 6. Ex vivo permeation of RS from its solution and RS loaded gel formulations.  Data are reported as 603 
the mean ± S.D. of three independent experiments.  604 
 605 
 606 
3.10 In vivo study 607 
Table 2. Biochemical analysis of serum levels of bone turnover markers for the different treatment groups. Data are 608 
reported as the mean ± S.D. of four independent experiments. 609 
Experimental 
Group 
Treatment ALP (IU/l) 
Serum 
Calcium 
(Ca) 
(mg/dl) 
Serum 
Phosphorus 
(P) (mg/dl) 
Serum 
creatinine 
(mg/dl) 
Group I IN saline 144.5±23.3 9.7±0.07 8.2±0.3 0.3±0.05 
0
200
400
600
800
1000
1200
1400
0 4 8 12 16 20 24 28 32 36 40 44 48
A
m
o
u
n
t 
p
e
rm
e
at
e
d
 p
e
r 
u
n
it
 a
re
a 
(µ
g
/c
m
2
)
Time (h)
F2
F4
RIS Solution
 24 
Group II SC DEX 383±111.7 8.6±0.2 3.7±3.3 0.5±0.07 
Group III DEX+IN RS 304.5±3.5 9.8±0.4 8.9±1.6 0.3±0.05 
Group IV DEX+IV RS 217±125.9 9.9±0.3 9.4±2.4 0.3±0.26 
Group V DEX+IN F2 206±62.2 10.1±0.4 9±1.4 0.3±0.05 
Group V1 DEX+IN F4 271±145.7 9.8±0.1 9.2±1.6 0.4±0.05 
 610 
In this study, an osteoporosis model was induced by SC administration of toxic doses of 611 
dexamethasone sodium phosphate (DEX) in experimental rats. DEX, as a glucocorticoid, has the 612 
potential to compromise the skeletal integrity, decrease osteoblastic activity and promote 613 
osteoblast and osteocyte apoptosis, resulting in increased fractures risk and augmented bone loss 614 
(O’Brien et al., 2004; Yao et al., 2008).  615 
Following induction of osteoporosis and RS treatment, biochemical markers, namely, alkaline 616 
phosphatase (ALP), calcium, inorganic phosphorus and creatinine, were tested. Serum ALP is an 617 
osteoblast-related protein that directly promotes osteoid formation and mineralization. It is a bone 618 
formation marker that used to indicate metabolic bone disease (Garnero and Delmas, 1993; 619 
Regidor et al., 2008). Serum calcium and phosphorus are also markers of osteoporotic bone and 620 
bone mineral content and creatinine is a marker of Bone resorption (Fazil et al., 2016).  621 
Table 2 depicts the biochemical examination of serum levels of bone turnover markers. Group-I, 622 
which acted as a negative control, exhibited normal serum levels of ALP and creatinine amounting 623 
to 144.5 ± 23.3 (IU/l)) and 0.3 ±0.05 (md/dl) respectively. On the other hand, the toxic group II, 624 
receiving SC DEX alone, showed a marked elevation in the serum levels of ALP and creatinine 625 
with respective values of 383 ± 111.7 (IU/l) and 0.5 ± 0.07 (mg/dl), the highest among all the 626 
tested groups, confirming the induction of GIO.  627 
This was reversed by RS in all RS treated groups (groups III-VI). A significant reduction in ALP 628 
and creatinine serum levels below the toxic level were demonstrated confirming promising 629 
recovery and capability of decreasing GIO risk. A notable significant increase of these values was 630 
obtained as compared to those of normal group (group I) (p˂0.05).  631 
Concerning serum calcium and phosphorus levels, the toxic group exhibited significantly reduced 632 
values among all the tested groups, proving osteoporosis formation. Following induction of 633 
osteoporosis, fragile conditions of the bone led to the release of calcium and phosphorus and their 634 
urinary excretion and hence, their reduced absorption (Fazil et al., 2016). All treated groups with 635 
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different forms of RIS showed higher calcium and phosphorus levels, proving the ability of RS to 636 
enhance the absorption of calcium and its bone deposition and to prevent bone-breaking tendency.  637 
 638 
3.11 Histopathological examination 639 
Histopathological examination of bones of animals of group I (normal control) (Fig. 7a) showed 640 
no histopathological alteration and the normal histological structure of the osteoblasts. The toxic 641 
group II histological manifestations exhibited focal areas of resorption with appearance of cavities 642 
and multiple osteoclasts as indicated by white arrows (Fig.7b), confirming osteoporosis induction.  643 
There were focal areas of resorption with few osteoclasts noticed in histological features in rats of 644 
group III treated with IN solution. The histopathology of bone was quite similar to the picture in 645 
rats of group IV, treated with IV solution, exhibiting focal area of osteogenesis with remodeling 646 
of the osteoblasts (Fig.7 c and d).  647 
As for rats of group V treated with F2, there were focal area of osteogenesis with osteoblasts 648 
remodeling as well as formation of dark basophilic lines of bone deposition as indicated by black 649 
arrows. The histopathological picture mirrored the results of treatment of osteoporosis (Fig.7e).  650 
Group VI treated with F4 shows the ultimate treatment as manifested by the angiogenesis of newly 651 
blood capillaries with dark basophilic line of bone deposition as indicated by white star. In 652 
addition, osteoblasts arrangement was recorded (Fig.7f), achieving promising recovery following 653 
osteoporosis induction.  654 
The prepared in situ gels were superior in their inhibitory effect as compared to IN and IV 655 
solutions, possibly due to proven low permeability of the hydrophilic drug. In addition, as for IN 656 
solution, the expected rapid wash out owing to nasal mucociliary clearance might contribute to its 657 
lower antiosteoporotic capability (Fazil et al., 2016). 658 
 659 
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 660 
Fig.7. Light micrograph of rat internal structure of bone treated with (a) IN saline, (b) SC DEX, (c) DEX+IN RS, (d) 661 
DEX+IV RS, (e) DEX+F2 and (f) DEX+F4. White arrows indicate focal areas of resorption with appearance of 662 
cavities, black arrows indicate focal area of osteogenesis and white star indicates angiogenesis of newly blood 663 
capillaries (White bar 100 µm). 664 
 665 
 666 
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3.12 Evaluation of nasal cytocompatability 667 
Mucoadhesive thermoresponsive hydrogels must be capable of delivering drugs in a sustained 668 
manner without compromising the host cell viability following nasal administration. In this regard, 669 
the effect of the prepared hydrogels on the cell viability of Calu-3 cells was investigated. Good 670 
cytocompatability was observed for F2 and F4 with no apparent cytotoxicity against the tested 671 
cells (cell viability >75%) after 24-h incubation at concentrations up to 250 and 62.5 µg/mL 672 
respectively (Fig. 8). It was only at hydrogel concentrations of 125 and 250 µg/mL that the 673 
cytotoxicity of F4 was significantly reduced. Lower cytocompatability values seen with F4 could 674 
be associated with its content of longer chains of PEGMA246-EE, possibly greatly interfering with 675 
the cell viability. Such values were comparable with other PEGMA-bearing copolymers utilized 676 
recently for drug delivery (Blanco-Fernandez et al., 2017). In addition, nonlinear PEG analogues 677 
had not induced cell death, even at a concentration as high as 10 mg /mL (Lutz, 2008).  678 
 679 
 680 
Fig. 8. Viability of Calu-3 cells by MTT assay after incubation with various concentrations of the test 681 
samples at 37 °C. Data are reported as the mean ± S.D. of three independent experiments.  682 
 683 
4. Conclusion 684 
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We suggest that the developed thermoresponsive in situ gels can contribute to the successful nasal 685 
delivery of RS. The characterization of the prepared in situ gels and the results of release, ex-vivo 686 
permeation experiments showed favourable rheological properties, mucoadhesive potential, 687 
sustained drug release and good permeability enhancement.  Non-irritating pH value and 688 
cytocompatability of in situ gels confirmed their reasonable nasal tolerability. Moreover, better in 689 
vivo inhibitory effect of RS-loaded in situ gels was achieved compared to IN and IV RS solutions 690 
on osteoporosis induction in experimental rats. Hence, these newly developed in situ gel 691 
formulations have characteristics which are appropriate for mucoadhesive thermoresponsive 692 
delivery systems. 693 
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